238 related articles for article (PubMed ID: 29126391)
1. MicroRNA-195 acts as an anti-proliferative miRNA in human melanoma cells by targeting Prohibitin 1.
Cirilo PDR; de Sousa Andrade LN; Corrêa BRS; Qiao M; Furuya TK; Chammas R; Penalva LOF
BMC Cancer; 2017 Nov; 17(1):750. PubMed ID: 29126391
[TBL] [Abstract][Full Text] [Related]
2. IL-10Rα expression is post-transcriptionally regulated by miR-15a, miR-185, and miR-211 in melanoma.
Venza I; Visalli M; Beninati C; Benfatto S; Teti D; Venza M
BMC Med Genomics; 2015 Dec; 8():81. PubMed ID: 26631117
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-485-5p represses melanoma cell invasion and proliferation by suppressing Frizzled7.
Wu J; Li J; Ren J; Zhang D
Biomed Pharmacother; 2017 Jun; 90():303-310. PubMed ID: 28364602
[TBL] [Abstract][Full Text] [Related]
4. MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer.
Li M; Chen W; Zhang H; Zhang Y; Ke F; Wu X; Zhang Y; Weng M; Liu Y; Gong W
Oncotarget; 2016 Dec; 7(50):83060-83070. PubMed ID: 27825112
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA 145 may play an important role in uveal melanoma cell growth by potentially targeting insulin receptor substrate-1.
Li Y; Huang Q; Shi X; Jin X; Shen L; Xu X; Wei W
Chin Med J (Engl); 2014; 127(8):1410-6. PubMed ID: 24762580
[TBL] [Abstract][Full Text] [Related]
6. MiR-377 targets E2F3 and alters the NF-kB signaling pathway through MAP3K7 in malignant melanoma.
Zehavi L; Schayek H; Jacob-Hirsch J; Sidi Y; Leibowitz-Amit R; Avni D
Mol Cancer; 2015 Mar; 14():68. PubMed ID: 25889255
[TBL] [Abstract][Full Text] [Related]
7. MiR-30a-5p confers cisplatin resistance by regulating IGF1R expression in melanoma cells.
Li Y; Zhang J; Liu Y; Zhang B; Zhong F; Wang S; Fang Z
BMC Cancer; 2018 Apr; 18(1):404. PubMed ID: 29642855
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met.
Yan D; Zhou X; Chen X; Hu DN; Dong XD; Wang J; Lu F; Tu L; Qu J
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1559-65. PubMed ID: 19029026
[TBL] [Abstract][Full Text] [Related]
9. miR-579-3p controls melanoma progression and resistance to target therapy.
Fattore L; Mancini R; Acunzo M; Romano G; Laganà A; Pisanu ME; Malpicci D; Madonna G; Mallardo D; Capone M; Fulciniti F; Mazzucchelli L; Botti G; Croce CM; Ascierto PA; Ciliberto G
Proc Natl Acad Sci U S A; 2016 Aug; 113(34):E5005-13. PubMed ID: 27503895
[TBL] [Abstract][Full Text] [Related]
10. Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b.
Vergani E; Di Guardo L; Dugo M; Rigoletto S; Tragni G; Ruggeri R; Perrone F; Tamborini E; Gloghini A; Arienti F; Vergani B; Deho P; De Cecco L; Vallacchi V; Frati P; Shahaj E; Villa A; Santinami M; De Braud F; Rivoltini L; Rodolfo M
Oncotarget; 2016 Jan; 7(4):4428-41. PubMed ID: 26684239
[TBL] [Abstract][Full Text] [Related]
11. Prohibitin silencing reverses stabilization of mitochondrial integrity and chemoresistance in ovarian cancer cells by increasing their sensitivity to apoptosis.
Gregory-Bass RC; Olatinwo M; Xu W; Matthews R; Stiles JK; Thomas K; Liu D; Tsang B; Thompson WE
Int J Cancer; 2008 May; 122(9):1923-30. PubMed ID: 18183577
[TBL] [Abstract][Full Text] [Related]
12. miR-137 inhibits proliferation of melanoma cells by targeting PAK2.
Hao S; Luo C; Abukiwan A; Wang G; He J; Huang L; Weber CE; Lv N; Xiao X; Eichmüller SB; He D
Exp Dermatol; 2015 Dec; 24(12):947-52. PubMed ID: 26186482
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-182 Suppresses Malignant Melanoma Proliferation by Targeting RECK.
Ding J; Zhu X; Chen X; Guan J; Li H
Clin Lab; 2020 Apr; 66(4):. PubMed ID: 32255303
[TBL] [Abstract][Full Text] [Related]
14. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
Guo GC; Wang JX; Han ML; Zhang LP; Li L
Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
[TBL] [Abstract][Full Text] [Related]
15. Targeting of TRX2 by miR-330-3p in melanoma inhibits proliferation.
Yao Y; Zuo J; Wei Y
Biomed Pharmacother; 2018 Nov; 107():1020-1029. PubMed ID: 30257313
[TBL] [Abstract][Full Text] [Related]
16. miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma.
Stark MS; Bonazzi VF; Boyle GM; Palmer JM; Symmons J; Lanagan CM; Schmidt CW; Herington AC; Ballotti R; Pollock PM; Hayward NK
Oncotarget; 2015 Jul; 6(19):17753-63. PubMed ID: 25980496
[TBL] [Abstract][Full Text] [Related]
17. Methylation-Mediated Silencing of MicroRNA-211 Decreases the Sensitivity of Melanoma Cells to Cisplatin.
Li N; Liu Y; Pang H; Lee D; Zhou Y; Xiao Z
Med Sci Monit; 2019 Mar; 25():1590-1599. PubMed ID: 30821276
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib.
Doudican NA; Orlow SJ
Oncogene; 2017 Jan; 36(3):423-428. PubMed ID: 27321184
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF.
Kim JH; Ahn JH; Lee M
Cancer Res Treat; 2017 Oct; 49(4):947-959. PubMed ID: 28052651
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-153-3p suppress cell proliferation and invasion by targeting SNAI1 in melanoma.
Zeng HF; Yan S; Wu SF
Biochem Biophys Res Commun; 2017 May; 487(1):140-145. PubMed ID: 28400282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
